Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Syntara Limited ( (AU:SNT) ).
The Garvan Institute of Medical Research in Sydney has secured a A$3 million grant from Australia’s Medical Research Future Fund to run two multicentre clinical studies in advanced pancreatic cancer, including a Phase I/II trial combining Syntara’s investigational LOX inhibitor amsulostat with standard chemotherapy. Under the collaboration, Syntara will provide the study drug and scientific and clinical support but will not contribute cash, allowing the company to expand into solid tumour research—building on preclinical data showing that targeting tumour fibrosis can improve chemotherapy penetration—while preserving its balance sheet and reinforcing its strategy of leveraging more than A$10 million in non-dilutive capital across four clinical programs. Recruitment for the pancreatic cancer trial is expected to begin in mid-2026 at major New South Wales cancer centres, incorporating precision medicine approaches such as deep molecular and genetic profiling to identify responsive patient subgroups and potentially inform broader application of anti-fibrotic strategies in other solid tumours, alongside Syntara’s already busy 2026 clinical agenda in iRBD, MDS and skin scarring.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited (ASX: SNT) is a clinical-stage drug development company focused on novel therapies targeting fibrosis and related mechanisms in cancer and haematological malignancies such as myelofibrosis (MF) and myelodysplastic syndromes (MDS), as well as neurological and scarring indications. Its lead candidates include the anti-fibrotic lysyl oxidase (LOX) inhibitor amsulostat (SNT-5505) and SNT-4728, which are being advanced through a diversified pipeline supported significantly by non-dilutive grant funding.
Average Trading Volume: 1,320,555
Technical Sentiment Signal: Sell
Current Market Cap: A$58.77M
For an in-depth examination of SNT stock, go to TipRanks’ Overview page.